Build your REPORT Express TM

BRAND NAME THERAPEUTIC AREA COUNTRIES CONTENT
  • Rationale and comments :
Progress Date advice Recommendation Type of limitation
Type of limitation
- - -
Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range